Table: Otsuka Holdings -9-MTH group results (IFRS)
Oct 31 (Reuters)-
Otsuka Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2024 Sep 30, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 1.73 trln 1.48 trln 2.31 trln
(+17.0 pct) (+16.8 pct) (+14.4 pct)
Operating 261.05 202.65 320.00
(+28.8 pct) (+76.5 pct) (+129.2 pct)
Pretax
Net 191.67 161.71 240.00
(+18.5 pct) (+45.6 pct) (+97.3 pct)
EPS Basic 353.33 yen 297.99 yen 443.24 yen
Ann Div 110.00 yen 120.00 yen
-Q2 Div 60.00 yen 50.00 yen
-Q4 Div 60.00 yen 60.00 yen
NOTE - Otsuka Holdings Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug